Patents by Inventor Vijay Naringrekar

Vijay Naringrekar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Romidepsin formulations and uses thereof
    Patent number: 9795650
    Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: October 24, 2017
    Assignee: Celgene Corporation
    Inventors: Lianfeng Huang, Ho-Wah Hui, Vijay Naringrekar, Gang Yang
  • Romidepsin formulations and uses thereof
    Patent number: 9782451
    Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: October 10, 2017
    Assignee: Celgene Corporation
    Inventors: Lianfeng Huang, Ho-Wah Hui, Vijay Naringrekar, Gang Yang
  • ROMIDEPSIN FORMULATIONS AND USES THEREOF
    Publication number: 20170007665
    Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.
    Type: Application
    Filed: September 20, 2016
    Publication date: January 12, 2017
    Inventors: Lianfeng HUANG, Ho-Wah HUI, Vijay NARINGREKAR, Gang YANG
  • ROMIDEPSIN FORMULATIONS AND USES THEREOF
    Publication number: 20170000845
    Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.
    Type: Application
    Filed: September 14, 2016
    Publication date: January 5, 2017
    Inventors: Lianfeng HUANG, Ho-Wah HUI, Vijay NARINGREKAR, Gang YANG
  • ROMIDEPSIN FORMULATIONS AND USES THEREOF
    Publication number: 20160367625
    Abstract: Provided herein are formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation is a combination of romidepsin and mannitol.
    Type: Application
    Filed: September 6, 2016
    Publication date: December 22, 2016
    Inventors: Lianfeng HUANG, Ho-Wah HUI, Victor PEYKOV, Willard R. FOSS, Vijay NARINGREKAR, Mei LAI
  • Romidepsin formulations and uses thereof
    Patent number: 9468664
    Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: October 18, 2016
    Assignee: Celgene Corporation
    Inventors: Lianfeng Huang, Ho-Wah Hui, Vijay Naringrekar, Gang Yang
  • Romidepsin formulations and uses thereof
    Patent number: 9463215
    Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: October 11, 2016
    Assignee: Celgene Corporation
    Inventors: Lianfeng Huang, Ho-Wah Hui, Vijay Naringrekar, Gang Yang
  • ROMIDEPSIN FORMULATIONS AND USES THEREOF
    Publication number: 20160067304
    Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.
    Type: Application
    Filed: November 17, 2015
    Publication date: March 10, 2016
    Inventors: Lianfeng HUANG, Ho-Wah HUI, Vijay NARINGREKAR, Gang YANG
  • ROMIDEPSIN FORMULATIONS AND USES THEREOF
    Publication number: 20160067303
    Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.
    Type: Application
    Filed: November 17, 2015
    Publication date: March 10, 2016
    Inventors: Lianfeng HUANG, Ho-Wah HUI, Vijay NARINGREKAR, Gang YANG
  • ROMIDEPSIN FORMULATIONS AND USES THEREOF
    Publication number: 20150182584
    Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.
    Type: Application
    Filed: December 23, 2014
    Publication date: July 2, 2015
    Inventors: Lianfeng HUANG, Ho-Wah HUI, Vijay NARINGREKAR, Gang YANG
  • ROMIDEPSIN FORMULATIONS AND USES THEREOF
    Publication number: 20150051157
    Abstract: Provided herein are formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation is a combination of romidepsin and mannitol.
    Type: Application
    Filed: October 17, 2014
    Publication date: February 19, 2015
    Inventors: Lianfeng HUANG, Ho-Wah HUI, Victor PEYKOV, Willard R. FOSS, Vijay NARINGREKAR, Mei LAI
  • ARIPIPRAZOLE COMPLEX FORMULATION AND METHOD
    Publication number: 20120053145
    Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: November 3, 2011
    Publication date: March 1, 2012
    Inventors: MANOJ NERURKAR, Vijay Naringrekar
  • ARIPIPRAZOLE COMPLEX FORMULATION AND METHOD
    Publication number: 20110160224
    Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: March 11, 2011
    Publication date: June 30, 2011
    Inventors: Manoj NERURKAR, Vijay NARINGREKAR
  • Sustained release glp-1 receptor modulators
    Publication number: 20100022457
    Abstract: The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.
    Type: Application
    Filed: November 8, 2006
    Publication date: January 28, 2010
    Inventors: Feng Qian, William R. Ewing, Claudio Mapelli, Douglas James Riexinger, Ving G. Lee, Richard B. Sulsky, Yeheng Zhu, Tasir Shamsul Haque, Rogelio L. Martinez, Vijay Naringrekar, Nina Ni, Lori S. Burton
  • ARIPIPRAZOLE COMPLEX FORMULATION AND METHOD
    Publication number: 20090186903
    Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: April 2, 2009
    Publication date: July 23, 2009
    Inventors: Manoj Nerurkar, Vijay Naringrekar
  • Aripiprazole complex formulation and method
    Patent number: 7550445
    Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: June 23, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Manoj Nerurkar, Vijay Naringrekar
  • Sustained release GLP-1 receptor modulators
    Patent number: 7534763
    Abstract: The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: May 19, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Feng Qian, William R. Ewing, Claudio Mapelli, Douglas James Riexinger, Ving G. Lee, Richard B. Sulsky, Yeheng Zhu, Tasir Shamsul Haque, Rogelio L. Martinez, Vijay Naringrekar, Nina Ni, Lori S. Burton
  • Controlled release sterile injectable aripiprazole formulation and method
    Publication number: 20080112986
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 15, 2008
    Inventors: Janusz Kostanski, Takakuni Matsuda, Manoj Nerurkar, Vijay Naringrekar
  • Controlled release sterile injectable aripiprazole formulation and method
    Publication number: 20080112985
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 15, 2008
    Inventors: Janusz Kostanski, Takakuni Matsuda, Manoj Nerurkar, Vijay Naringrekar
  • Controlled release sterile injectable aripiprazole formulation and method
    Publication number: 20080107745
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 8, 2008
    Inventors: Janusz Kostanski, Takakuni Matsuda, Manoj Nerurkar, Vijay Naringrekar